Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Apr;273(1):320-6.

Adenosine receptor activation modulates intraocular pressure in rabbits

Affiliations
  • PMID: 7714784

Adenosine receptor activation modulates intraocular pressure in rabbits

C E Crosson. J Pharmacol Exp Ther. 1995 Apr.

Abstract

The relatively selective adenosine A1 agonists N6-cyclohexy-ladenosine (CHA), R(-)-N6-(2-phenylisopropyl)adenosine (R-PIA) and S(+)-N6-(2-phenylisopropyl)adenosine (S-PIA); the A2a agonist 2-p-carboxyethyl)phenethyl-amino-5'-N-ethylcarbox-amidoadenosin e (CGS-21680) and the nonselective A2 agonist 2-phenylaminoadenosine (CV-1808) were evaluated in vivo for their effects on aqueous humor dynamics and in vitro for their action on 3H-norepinephrine release and cAMP accumulation in the isolated iris/ciliary body. These studies demonstrated that adenosine agonists can modulate intraocular pressure (IOP). Except for CV-1808, the topical administration of adenosine agonists produced a unilateral dose-related reduction in IOP with a potency order of R-PIA = CHA > CGS-21680 > S-PIA > CV-1808. Although CV-1808 did not lower IOP, it did induce a significant dose-dependent rise in IOP. Neither the reduction in IOP induced by R-PIA nor the rise in IOP induced by CV-1808 was affected by surgical removal of the superior cervical ganglion. However, the adenosine agonist-induced reduction in IOP was associated with a significant decrease in aqueous flow. In vitro studies demonstrated that the adenosine agonists did not alter the evoked release of 3H-norepinephrine; however, they were effective in suppressing the accumulation of cAMP, and this response was blocked by pretreatment with the antagonist 8-cyclopentyl-1,3-dimethylxanthine. These studies provide evidence that adenosine agonists lower IOP by activating postjunctional adenosine A1 receptors. This response is associated with a reduction in aqueous flow and the modulation of cAMP in the iris/ciliary body.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources